Kaposi sarcoma in a patient treated with upadacitinib for rheumatoid arthritis
Cynthia Fournier, Maxwell Sauder, Zaid Saeed Kamil, Marcus O. Butler
Abstract
Upadacitinib is a Janus kinase (JAK) inhibitor that inhibits JAK1. It is approved for rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, and ulcerative colitis. Kaposi sarcoma (KS) is a neoplasm of lymphatic endothelium-derived cells infected by human herpesvirus 8 (HHV-8).1 KS is subdivided into the following 4 clinical variants: classic, African endemic, because of iatrogenic immunosuppression, and associated with AIDS.1 Many immunosuppressants have been reported to trigger KS. To our knowledge, we report the first case of KS induced by upadacitinib.
Topics & Concepts
MedicineRheumatoid arthritisJanus kinaseImmunosuppressionPsoriatic arthritisDermatologyTofacitinibSarcomaJanus kinase inhibitorUlcerative colitisImmunologyInternal medicinePathologyCytokineDiseaseViral-associated cancers and disordersLymphoma Diagnosis and TreatmentAutoimmune and Inflammatory Disorders Research